SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of POINT Biopharma Global, Inc. ("POINT") (NASDAQ:PNT) breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company.
On October 3, 2023, POINT announced that it had entered a deal with Eli Lilly and Company. Under the terms of this agreement, shareholders will receive $12.50 per share in an all-cash offer.
The investigation concerns whether the POINT board failed ...
PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?>Full story available on Benzinga.com